Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
10 nov. 2022 08h00 HE
|
Myriad Genetics, Inc.
UroSuite helps healthcare providers personalize treatment with easier access to biomarker, germline and somatic testing from a single source. SALT LAKE CITY, Nov. 10, 2022 (GLOBE NEWSWIRE) --...
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
03 nov. 2022 18h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today JCO Precision Oncology has published a...
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
01 nov. 2022 09h10 HE
|
Myriad Genetics, Inc.
$67.5 million tuck-in acquisition strengthens Myriad’s Women’s Health portfolio of prenatal productsFast-growing SneakPeek test has helped 750,000 parents learn baby’s gender from home – earliest...
Myriad Genetics Reports Third Quarter Financial Results
01 nov. 2022 09h05 HE
|
Myriad Genetics, Inc.
Highlights: Revenue of $156.4 million for the quarter ended September 30, 2022. Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3...
Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
31 oct. 2022 16h30 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today the election of Paul M. Bisaro to its...
Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022
26 oct. 2022 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third-quarter earnings conference call on...
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
28 sept. 2022 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey it conducted...
Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com câncer de mama na pré-menopausa
31 août 2022 08h00 HE
|
Myriad Genetics, Inc.
O teste EndoPredict, da Myriad Genetics, identificou com precisão mulheres na pré-menopausa com câncer de mama ER+, HER2- que poderiam evitar, com segurança, a quimioterapia adjuvante SALT LAKE CITY,...
Un nuovo studio pubblicato sulla rivista Clinical Cancer Research mette in evidenza l’impiego del test EndoPredict per indicare quale trattamento adottare in pazienti con tumore al seno in premenopausa
31 août 2022 08h00 HE
|
Myriad Genetics, Inc.
Il test EndoPredict di Myriad Genetics ha identificato in modo accurato le donne in premenopausa con carcinoma mammario ER+, HER2- che potevano con sicurezza evitare la chemioterapia adiuvante SALT...
Une nouvelle étude publiée dans le Clinical Cancer Research Journal met en avant l’utilisation du test EndoPredict pour éclairer les décisions thérapeutiques chez les patientes préménopausées atteintes d’un cancer du sein
31 août 2022 08h00 HE
|
Myriad Genetics, Inc.
Le test EndoPredict de Myriad Genetics identifie avec précision les femmes préménopausées atteintes d'un cancer du sein RE+, HER2- qui pourraient éviter une chimiothérapie adjuvante sans perte de...